Rash from EGFR inhibitors: opportunities and challenges for palliation.
The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment.
Solomon
Benjamin M
BM
Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. jatoi.aminah@mayo.edu.
Jatoi
Aminah
A
D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy*; D010166:Palliative Care; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*
D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
Clin Cancer Res. 2005 Sep 15;11(18):6414-21
16166415
Nat Rev Cancer. 2006 Oct;6(10):803-12
16990857
JAMA. 2003 Oct 22;290(16):2149-58
14570950
J Clin Oncol. 2004 Apr 1;22(7):1201-8
14993230
Oncologist. 2007 May;12(5):577-83
17522246
Oncology (Williston Park). 2007 Oct;21(11 Suppl 5):34-6
18154217
FEBS Lett. 2006 Mar 20;580(7):1859-64
16516204
Br J Dermatol. 2002 Sep;147(3):598-601
12207609
Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):42-5
17254038
Cancer Biol Ther. 2006 Apr;5(4):340-2
16808060
Clin Cancer Res. 2007 Jul 1;13(13):3913-21
17606725
Curr Oncol Rep. 2006 Jul;8(4):269-74
17254526
J Support Oncol. 2006 May;4(5):236-8
16724647
Can Fam Physician. 2002 Apr;48:712-6
12046366
J Clin Oncol. 2007 May 20;25(15):1960-6
17452677
Br J Dermatol. 2001 Jun;144(6):1169-76
11422037
Cancer Res. 2002 Sep 1;62(17):4922-8
12208742
Arch Dermatol. 1998 Apr;134(4):454-8
9554297
Clin Exp Dermatol. 2008 Jan;33(1):46-9
17983455
Eur J Cancer. 2007 Mar;43(5):845-51
17289377
Biochim Biophys Acta. 2007 Apr;1770(4):687-93
17276010
J Clin Oncol. 2007 Dec 1;25(34):5390-6
18048820